---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-157998"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:16:25.231242+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics announces $50M private placement; extends cash runway into Q1 2025

## Summary
- Gross proceeds of ~$50M from sale of ~17.7M shares, ~2.4M pre-funded warrants, and ~10.0M purchase warrants at $2.4925 per unit.
- Pre-funded warrants exercisable immediately at $0.001/share, expire May 2028; purchase warrants exercisable from Nov 2023 at $2.673/share, expire Nov 2028.
- Cash, cash equivalents and short-term investments stood at $82.7M as of Q1 2023; combined with net proceeds expected to fund operations into Q1 2025.
- Cantor Fitzgerald and William Blair acted as joint lead placement agents; H.C. Wainwright as co-placement agent.

## SEC filing metadata
- accession: 0001193125-23-157998
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/0001193125-23-157998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/d515559d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-157998
- JSON: https://secwatch.observer/filing/0001193125-23-157998.json
- Plain text: https://secwatch.observer/filing/0001193125-23-157998.txt

## Key facts
- Material Agreements
  Lyra Therapeutics, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at aggregate gross proceeds of approximately $50.0 million (effective 2023-05-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers named therein
  - Value: aggregate gross proceeds of approximately $50.0 million
  - Effective: 2023-05-25
  source text: On May 25, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to sell securities to the Investors in a private placement (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312523157998/0001193125-23-157998-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.